India High Court To Decide If DCGI Can Approve Generic Of Patented Drug
This article was originally published in PharmAsia News
Executive Summary
India's Supreme Court blocked an effort by Bayer AG of Germany to keep Indian generics maker Cipla from marketing its version of Nexavar (sorafenib) for treating cancer